Platelet number and function alterations in preclinical models of sterile inflammation and sepsis patients : implications in the pathophysiology and treatment of inflammation
Copyright © 2022 Elsevier Ltd. All rights reserved..
Platelets are the blood cells in charge of maintaining the body hemostasis, recognising the damaged vessel wall, and providing the appropriate cellular surface for the coagulation cascade to act locally. Additionally, platelets are active immunomodulators. At the crossroads of hemostasis and inflammation, platelets may exert either beneficial actions or participate in pathological manifestations, and have been associated with the prothrombotic nature of multi-organ failure in systemic inflammation. Platelet number alterations have been reported in septis, and platelet transfusions are given to thrombocytopenic patients. However, the risk to develop transfusion related acute lung injury (TRALI) is higher in sepsis patients. In this manuscript we show that platelets produced during inflammation in preclinical mouse models of sterile inflammation display lower aggregation capacity when stimulating certain receptors, while responses through other receptors remain intact, and we name them "inflammation-conditioned" platelets. In a cohort of sepsis patients, we observed, as previously reported, alterations in the number of platelets and platelet hyperreactivity. Furthermore, we identified a receptor-wise platelet aggregation response disbalance in these patients, although not similar to platelets from preclinical models of sterile inflammation. Interestingly, we generated evidence supporting the notion that platelet aggregation capacity disbalance was partially triggered by plasma components from sepsis patients. Our findings have implications in the indication of platelet transfusions in sepsis patients: Are fully functional platelets suitable for transfusion in sepsis patients? Current Clinical Trials (RESCUE) will answer whether platelet production stimulation with thrombopoietin receptor agonists (TPO-RAs) could be a substitute of platelet transfusions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis - 61(2022), 2 vom: 11. Apr., Seite 103413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Villa-Fajardo, María [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Flow cytometry |
|---|
| Anmerkungen: |
Date Completed 24.05.2022 Date Revised 24.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.transci.2022.103413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33818791X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33818791X | ||
| 003 | DE-627 | ||
| 005 | 20231226000117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transci.2022.103413 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1127.xml |
| 035 | |a (DE-627)NLM33818791X | ||
| 035 | |a (NLM)35288057 | ||
| 035 | |a (PII)S1473-0502(22)00075-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Villa-Fajardo, María |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Platelet number and function alterations in preclinical models of sterile inflammation and sepsis patients |b implications in the pathophysiology and treatment of inflammation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2022 | ||
| 500 | |a Date Revised 24.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Platelets are the blood cells in charge of maintaining the body hemostasis, recognising the damaged vessel wall, and providing the appropriate cellular surface for the coagulation cascade to act locally. Additionally, platelets are active immunomodulators. At the crossroads of hemostasis and inflammation, platelets may exert either beneficial actions or participate in pathological manifestations, and have been associated with the prothrombotic nature of multi-organ failure in systemic inflammation. Platelet number alterations have been reported in septis, and platelet transfusions are given to thrombocytopenic patients. However, the risk to develop transfusion related acute lung injury (TRALI) is higher in sepsis patients. In this manuscript we show that platelets produced during inflammation in preclinical mouse models of sterile inflammation display lower aggregation capacity when stimulating certain receptors, while responses through other receptors remain intact, and we name them "inflammation-conditioned" platelets. In a cohort of sepsis patients, we observed, as previously reported, alterations in the number of platelets and platelet hyperreactivity. Furthermore, we identified a receptor-wise platelet aggregation response disbalance in these patients, although not similar to platelets from preclinical models of sterile inflammation. Interestingly, we generated evidence supporting the notion that platelet aggregation capacity disbalance was partially triggered by plasma components from sepsis patients. Our findings have implications in the indication of platelet transfusions in sepsis patients: Are fully functional platelets suitable for transfusion in sepsis patients? Current Clinical Trials (RESCUE) will answer whether platelet production stimulation with thrombopoietin receptor agonists (TPO-RAs) could be a substitute of platelet transfusions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Flow cytometry | |
| 650 | 4 | |a Platelet aggregation | |
| 650 | 4 | |a Platelet transfusion | |
| 650 | 4 | |a Sepsis patient | |
| 650 | 4 | |a TRALI | |
| 700 | 1 | |a Palma, María Cecilia Yáñez |e verfasserin |4 aut | |
| 700 | 1 | |a Acebes-Huerta, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Botía, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Meinders, Marjolein |e verfasserin |4 aut | |
| 700 | 1 | |a Nolte, Martijn A |e verfasserin |4 aut | |
| 700 | 1 | |a Cuesta, Celina Benavente |e verfasserin |4 aut | |
| 700 | 1 | |a Eble, Johannes A |e verfasserin |4 aut | |
| 700 | 1 | |a Del Castillo, Juan González |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Sánchez, Francisco Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez, Laura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis |d 2001 |g 61(2022), 2 vom: 11. Apr., Seite 103413 |w (DE-627)NLM114008043 |x 1473-0502 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:2 |g day:11 |g month:04 |g pages:103413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.transci.2022.103413 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 2 |b 11 |c 04 |h 103413 | ||